Severe mental illnesses such as schizophrenia, bipolar disorder and major depression are 56% more common in people who have chronic kidney disease compared to those who don’t have it, according to a ...
Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...
A comprehensive study published in the journal of BMJ Rheumatic & Musculoskeletal Diseases focused on the prevalence and risk ...
14h
HealthDay on MSNVitamin D Deficiency Tied to Depression Risk With Chronic Kidney DiseaseVitamin D deficiency (VDD) is independently associated with increased depression risk in patients with chronic kidney disease ...
The excess payments Medicare Advantage plans receive for higher risk scores may be more influenced by differences in coding practices rather than actual differences in disease burden between MA and ...
Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approvalWALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded ...
The TGFR, which includes Lumitrace (relmapirazin), was approved on January 17th by the U.S. Food and Drug Administration (FDA). MediBeacon continues development of future TGFR products including a ...
There used to be no specific treatments for heart failure with preserved ejection fraction, but recent clinical trials show ...
Ardelyx (ARDX) announced the approval of a New Drug Application, NDA, by China’s Center for Drug Evaluation of the National Medical Products ...
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines ...
The following is a summary of “Development of a prediction model for in-hospital mortality in immunocompromised chronic kidney diseases patients with severe infection,” published in the February 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results